MedTrace Logo

Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML

NCT07338357 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-01-13

No results posted yet for this study

Summary

A study to evaluate the safety and preliminary efficacy of CLL-1-targeted CAR-T cell therapy in children aged 3 to 18 years with relapsed or refractory acute myeloid leukemia (r/r AML).

Conditions

  • AML (Acute Myeloid Leukemia)
  • CAR-T

Interventions

BIOLOGICAL

CAR-T

A infusion of CLL-1 CAR-T cells following a lymphodepleting chemotherapy regimen.

Sponsors & Collaborators

  • Guangzhou Bio-gene Technology Co., Ltd

    collaborator INDUSTRY

  • First Affiliated Hospital of Guangxi Medical University

    lead OTHER

Principal Investigators

  • Yunyan He, PhD · First Affiliated Hospital of Guangxi Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-05
Primary Completion
2028-10-31
Completion
2028-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07338357 on ClinicalTrials.gov